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Very few low- income countries have developed national plans to achieve the viral 
hepatitis elimination targets set in the World Health Organization (WHO) strategy. 
We reviewed the policy environment, strategies and challenges on the fight against 
viral hepatitis in Zimbabwe. The review focussed on the Ministry of Health and Child 
Care (MoHCC) policy documents, strategic plans and reports. We performed key in-
formant interviews to enhance evidence generated from the document review. Twelve 
documents were reviewed and interviews with 10 key informants were completed. 
The MoHCC established a technical working group to work towards elimination of 
viral hepatitis. The technical working group drafted a strategic plan for elimination 
of viral hepatitis; however, it is still awaiting implementation. Key strategies that are 
working well include screening of donated blood for transfusion, safe injection prac-
tices and hepatitis B virus (HBV) three- dose vaccination. Current challenges in the 
drive towards elimination of viral hepatitis include poor to non- existent surveillance 
systems, lack of epidemiological data, absence of the HBV vaccine birth dose and 
lack of systematic screening and treatment services for viral hepatitis. In conclusion, 
despite political will demonstrated towards achieving viral hepatitis elimination, sub-
stantial investment and work are required to implement the strategic plan and realize 
significant success.
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Statement of Significance
This research paper summarizes the progress made so far in the elimination of viral hepatitis in 
Zimbabwe. The manuscript spells out the strategies that are working and identifies the areas 
that are lagging behind. Information presented in this paper is helpful to the general public 
and policymakers to raise awareness and help them formulate strategies to achieve elimination 
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1  |  INTRODUC TION
Viral hepatitis is a public health threat due to its increasing con-
tribution to morbidity and mortality.1,2 Although there are five 
hepatotropic viruses (A, B, C, D, E), hepatitis B (HBV) and C (HCV) 
account for 91% morbidity and 96% mortality.3 In 2015, complica-
tions linked to chronic HBV and HCV accounted for 1.34 million 
deaths globally, more deaths than due to HIV/AIDS.1 Sub- Saharan 
Africa bears a substantial burden of viral hepatitis, with 60 mil-
lion and 10– 15 million people living with chronic HBV4 and HCV5 
infection, respectively.6
There are limited data on the general population prevalence and 
number of deaths caused by viral hepatitis in Zimbabwe. The WHO 
scorecard (2019) estimated the seroprevalence of HBV at 10.1% and 
approximately 1.6 million chronic infections.7 Modelling studies es-
timated the prevalence of HBV to be 9% with 2500 deaths occurring 
annually.8 Currently, there are no official national estimates of HCV 
burden. Experts estimate the prevalence of HCV to be around 1– 2% 
in the general population but likely higher in high- risk populations. 
A greater proportion of the chronically infected people remains un-
aware of their status. The two infections have long latent periods 
where the infected are asymptomatic making viral hepatitis a silent 
killer.
In 2016, WHO launched an ambitious but achievable global strat-
egy to eliminate viral hepatitis as a public health threat by 2030.9 
The availability of highly effective directly acting antivirals (DAAs) 
therapy for HCV makes the elimination targets achievable.10– 12 
Furthermore, modelling studies predicted the feasibility of the 
global elimination of viral hepatitis.13– 15 Micro elimination, defined 
as a strategy where one group of people or one geographical area is 
targeted at a time,16 has been proposed to achieve national elimina-
tion targets for HCV. Despite all these advances, most African coun-
tries lag behind in formulating policies and implementing strategies 
to achieve elimination. Lack of national coordination, political will 
and financial resources are the major reasons for the slow pace at 
which elimination efforts are moving.4,5,17 In Zimbabwe, it is unclear 
whether achieving the elimination targets by 2030 is feasible, hence 
evaluating the status quo is pivotal. Several countries including, for 
example Rwanda, Georgia and Egypt, which have reported substan-
tial progress towards elimination used different frameworks to fight 
viral hepatitis.18 Universal health coverage, development of national 
plan, development of investment case and testing and linkage to 
care have been used in these countries as drivers for elimination.18 
The choice of the framework largely depends on the epidemiolog-
ical, health policy, financial and political context. In this study, we 
aimed to review the policy environment, strategies and gaps and 
make recommendations towards the elimination of viral hepatitis in 
Zimbabwe.
2  |  METHODS
We reviewed health policy documents and interviewed key inform-
ants to collect data. Policy documents, strategy documents and re-
ports from the MoHCC that are relevant to the fight against viral 
hepatitis were identified and reviewed. Inclusion of the documents 
in the review and the review was based on the alignment of their 
objectives; policy directions and strategies to the five priority areas 
identified by WHO in the Global Health Sector Strategy on Viral 
Hepatitis.9 These priority areas are information for focussed action, 
interventions for impact, delivering equity, financing for sustainabil-
ity and innovation for acceleration. The documents were obtained 
by searching the terms ‘health policies of Zimbabwe’ and ‘health 
strategies of Zimbabwe’ on google and google scholar. Additional 
policy documents were suggested and provided by the key inform-
ants. Appendix 1 provides a summary of the documents that we re-
viewed. The key informants were representatives from the MoHCC, 
Medicines Control Authority of Zimbabwe (MCAZ), National Blood 
Services Zimbabwe (NBSZ), pharmaceutical wholesalers and gas-
troenterologists. These stakeholders were chosen because they are 
involved in policy formulation or in activities spelt out in the WHO 
strategy.
2.1  |  Data analysis
The written data scripts obtained from the policy review and the 
key informant interviews were analysed using thematic analysis.19 
The five priority areas in the WHO Global Health Sector Strategy on 
Viral Hepatitis were adopted as themes for the analysis.
2.2  |  Ethical considerations
Ethical approval to conduct the study was granted by the Joint 
Research Ethics Committee for University of Zimbabwe College of 
Health Sciences and Parirenyatwa Hospitals (JREC/111/2020). All 
the key informants signed informed consent before participating in 
the study.
3  |  RESULTS
3.1  |  Policy environment
A total of 15 and 39 documents were obtained from the MoHCC and 
UNICEF Zimbabwe websites, respectively. Forty- five documents 
were not relevant to viral hepatitis and were not reviewed. Three 
targets, respectively. Other low- to- middle- income countries can also draw lessons from the 
strategies that are working well highlighted in this paper.
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additional documents were suggested and provided by the key in-
formant at the MoHCC and were included in the review. In total, 12 
documents were reviewed as shown in Figure 1.
The Constitution of Zimbabwe stipulates the right to have ac-
cess to basic healthcare services for every person20 and the Public 
Health Act lists viral hepatitis as a notifiable disease.21 The Viral 
Hepatitis Rapid Assessment carried out in 201722 provided a basis 
for the drafting of Strategic Plan for Control and Elimination of Viral 
Hepatitis in Zimbabwe.23 The strategic plan covers the period 2019 
to 2022, focussing mainly on HBV and HCV. The objectives and pri-
orities of the plan are summarized in Table 1. The overarching goals 
of the plan are to reduce incidence of viral hepatitis by 90% and 
mortality by 65% by 2030. The strategic plan is premised on a pub-
lic health model where viral hepatitis services will be offered from 
the primary healthcare centre up to the tertiary level. However, the 
strategic plan does not explicitly state- specific institutions that are 
responsible for implementation or the timelines for accomplishing 
the activities that are listed.
One of the strategic documents reviewed was the National 
Health strategy (2016– 2020)24 which had its motto as ‘equity and 
quality: leaving no one behind.’ Equity and quality are key principles 
guiding the elimination of viral hepatitis. The situational analysis pre-
sented in the National Health strategy identifies viral hepatitis as 
a common cause of chronic liver disease and ranks viral hepatitis 
18th out of the top 20 most common causes of death in Zimbabwe. 
The ranking provides the basis for identifying priority diseases 
areas, which feed into the Zimbabwe National Medicines Policy 
which directs efforts to ensure availability and access to essential 
medicines.25 The policy provides for drafting of Essential Medicines 
List and Standard Treatment Guidelines for Zimbabwe (EDLIZ).26 
Although the management of complications of cirrhosis is described 
in EDLIZ, treatment guidelines for HCV or HBV are not explicitly 
described. Other key pieces of policy that were reviewed were the 
Health Financing policy and strategy documents.27,28 These docu-
ments spelled out approaches to ensure adequate resource mobiliza-
tion, equitable resource allocation, efficient purchasing mechanisms 
and household financial protection in health care.27,28 These strate-
gies include strengthening domestic funding, risk pooling and cross 
subsidizing and incentivizing provision efficient healthcare services. 
Although there is no explicit mentioning of viral hepatitis, the pol-
icy directions are broad and applicable to the elimination drive. The 
Zimbabwe Extended HIV and AIDS Strategy described strategies to 
increase condom use, which is also useful in reducing sexual trans-
mission of HCV.29
3.2  |  Strategies towards elimination
3.2.1  |  Information for focussed effort
Despite having all forms of viral hepatitis listed as notifiable in the 
Public Health Act,23 notifications are not happening in practice. 
The Notifiable Disease Surveillance System (NDSS) requires re-
porting, aggregation and analysis of all suspected and confirmed 
cases of viral hepatitis from all health facilities.30 The MoHCC at-
tributed the lack of reporting to lack of knowledge among health 
workers and lack of diagnostic kits. Laboratory- based surveil-
lance occurred in the past but stopped due to unknown reasons. 
Surveillance of sequelae of chronic viral hepatitis is also unavail-
able. However, mortality data from liver cancers are available 
from the Zimbabwe National Cancer Registry.31 As of 2015, liver 
cancers contributed 6% to the total deaths due to cancer.31 The 
cancer registry largely depends on post- mortem and death cer-
tificates data and, therefore, does not provide information on the 
F I G U R E  1  Flowchart of the documents 
included for review. MoHCC, Ministry of 
Health and Child Care, UNICEF, United 
Nations Children's Fund
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aetiology of the liver cancers. Data on the prevalence of HBV or 
HCV are limited to very small studies, old studies, or studies in 
pregnant women and blood donors.32– 34
3.3  |  Interventions for impact
3.3.1  |  Blood donor screening
Blood donor screening is performed by the NBSZ. The NBSZ stated 
that they adhere to WHO blood safety guidelines.35 The first line 
to ensure blood safety is the education on HIV, viral hepatitis and 
syphilis to equip potential donors with information allowing them 
to self- screen. In the second level of screening, prospective donors 
complete the donor and enrolment and assessment form which ex-
plore their risk profile pertaining to HIV, HCV, HBV, syphilis, drug 
abuse and sexual practices. After enrolment, further counselling is 
done to provide the donors with more information on transfusion 
transmissible infections (TTIs). In the laboratory, all collected blood 
is screened using highly sensitive tests for initial screening and highly 
specific tests for confirmation. The prevalence of TTIs in donated 
blood over an eight- year period is shown in Figure 2. The NBSZ is 
currently using the Abbott Architect i2000SR serology platforms. 
Nucleic acid testing (NAT), a more sensitive and specific method for 
virus detection, has been introduced in many blood centres globally 
and shown to improve blood safety. In an economic evaluation, the 
introduction of NAT for testing of TTIs compared with serology- 
based screening was deemed not cost effective in Zimbabwe.36 
Viremia is not being confirmed or quantified for anti- HCV reactive 
cases due to unavailability of polymerase chain reaction (PCR) tests.
3.3.2  |  Vaccination
The WHO recommended universal HBV vaccination for children 
under five led to significant decline in HBV in that population in 
Africa.1,37 The MoHCC indicated that Zimbabwe adopted the uni-
versal HBV vaccination in 1996. A pentavalent vaccine is given at 6, 
10 and 14 weeks. Figure 3 shows the HBV vaccination coverage over 
a 24 year period. In 2009, the WHO recommended that all countries 
include an HBV birth dose where a monovalent vaccine should be 
administered within 24 h of birth.38 Evidence shows that full vac-
cine coverage with three doses and the inclusion of the birth dose is 
vital in reducing vertical, and horizontal transmission in early life.39 
Despite this evidence, the birth dose is not routinely administered 
in Zimbabwe due to limited funds, unavailability of cold chain facili-
ties and difficulty in reaching infants within 24 h of birth. However, 
the MoHCC reported that the birth dose had been imprinted onto 
the paediatric immunization cards and planned for introduction. The 
card contains an immunization schedule and serves as a reminder 
TA B L E  1  The Zimbabwe national viral hepatitis strategic plan objectives and priorities
Strategic objective 1: Integrated, comprehensive and coordinated national 
response.
Priority area 1: Comprehensive public health responses
Priority area 2: Building health care workers capacity
Priority area 3: Advocacy and awareness
Strategic objective 2: Provision of diagnostics, care and treatment 
services
Priority area 1: Access to diagnostics
Priority area 2: Comprehensive care and treatment
Priority area 3: Clear referrals and linkage to care
Strategic objective 3: Prevent transmission of viral hepatitis
Priority area 1: Safety of blood and blood products
Priority area 2: Vaccination against hepatitis
Priority area 3: Infection prevention and control— injection safety
Priority area 4: Access to safe food and water
Priority area 5: Harm reduction
Priority area 6: Transmission prevention in correctional services
Strategic objective 4: strategic information systems, surveillance, 
monitoring and evaluation
Priority area 1: Monitoring and evaluation
Priority area 2: Health information systems
Priority area 3: Viral hepatitis surveillance system
Priority area 4: Operations research
F I G U R E  2  Transfusion Transmissible 
Infections Surveillance (2010– 2018): 
Reproduced with permission from 
National Blood Services Zimbabwe Annual 
Report 2018.62 HBV, hepatitis B virus, 
HCV, hepatitis C virus
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and monitoring tool for healthcare providers and the mother of all 
the required vaccines.
3.3.3  |  Harm reduction interventions
The MoHCC reported availability of the national infection preven-
tion and control guidelines, which were being adhered to at most 
health institutions at all levels. The guidelines spell out establish-
ment of infection control teams, personal protection equipment, 
injection safety, handling and sterilization of surgical equipment 
and waste disposal.40 The MoHCC reported that all health profes-
sionals in the institutions do use one syringe and needle per patient 
per time. Harm reduction interventions in terms of sexual behaviour 
ride on HIV prevention programmes, with no specific programme 
aimed at viral hepatitis. The messages include desisting from mul-
tiple sexual partners and consistent use of condoms. Viral hepatitis 
harm reduction interventions in men who have sex with men, people 
who inject drugs and commercial sex workers are currently not avail-
able in Zimbabwe. The size and behaviour of these populations are 
poorly characterized because of stigma and criminalization; hence, it 
is very difficult to design interventions that specifically target them. 
The Centre for Sexual Health and HIV/AIDS Research Zimbabwe, 
a private voluntary organization has done research to estimate the 
size and to understand HIV dynamics among commercial sex work-
ers.41,42 The harm reduction interventions are very functional in 
health institutions but need to be extended to key populations.
3.3.4  |  Screening and Treatment
The MoHCC, Laboratory directorate and medical officers revealed 
that routine viral hepatitis screening is currently not available. 
Screening for HBV and HCV is only done based on clinical suspicion 
of liver disease. The major constraint is limited laboratory capacity to 
carry out serology tests. HCV PCR quantification tests are currently 
unavailable in the public sector. Although infrastructure like labora-
tory buildings are available, equipment, reagents and assay kits are 
scarce. Most patients are referred to the private sector where they 
are required to pay high costs for diagnostic testing.
Guidelines on the management of sequelae of viral hepatitis are 
available in the EDLIZ 2015 edition; however, HBV and HCV treat-
ment are not covered. HIV/HBV co- infected patients are reportedly 
treated with tenofovir disoproxil fumarate (TDF) containing antiret-
roviral regimen, and the mono- infected patients are treated using 
TDF monotherapy. A survey by the MoHCC in 2017 revealed that 
only 20 patients in the public sector had been on TDF monotherapy 
over a period of 3 years.20 Low levels of HCV and HBV treatment 
coverage is due to limited drug supply. The MCAZ and the private 
pharmaceutical wholesaler companies revealed that a number of 
drug molecules useful in the treatment of HCV (DAAs) and HBV 
were either registered or in the process of registration as shown 
in Table 2. Wholesalers indicated there are drugs that are used in 
F I G U R E  3  Trends in Hepatitis B 
vaccination coverage in Zimbabwe (1995– 
2019)








Sofosbuvir Yes Registered in 2017
Daclatasvir Yes Estimated 2020
Hepatitis C combination
Sofosbuvir/daclatasvir Yes Estimated 2020
Sofosbuvir/ledipasvir Yes Registered in 2019
Hepatitis B
Entecavir Yes Registered in 2019
Telbivudine Yes Estimated 2020
Hepatitis B vaccine Yes Registered in 2029
Hepatitis A
Hepatitis A vaccine Yes Registered in 2014
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the management of viral hepatitis that are registered but not com-
mercialized due to perceived lack of market. Although many DAAs 
are not yet registered, doctors have been importing them using a 
special import permit for unregistered medicines issued by MCAZ. 
One wholesaler reported importing 70 units of sofosbuvir/ledipas-
vir (28 s) from India in 2019 under this facility. Another wholesaler 
reported importing HBV and Hepatitis A vaccines to augment gov-
ernment supplies. The pharmaceutical wholesalers reported having 
financial and warehousing capacity to import medicines in large 
quantities which can feed into the public health system. High cost of 
DAAs is a barrier to access of HCV treatment. Generic sofosbuvir/
ledipasvir was wholesaling at US$1125 for 12 weeks supply at the 
time of the study, a price out of reach for many patients. Treatment 
coverage of viral hepatitis unknown but is thought to be very low.
3.4  |  Financing for sustainability and 
delivering equity
The MoHCC revealed that the viral hepatitis strategic plan will be 
costed to determine the financial resources required for implemen-
tation. The major funding for the fight against viral hepatitis will be 
provided by the government. With the current economic challenges 
in the country, funding from the government is not expected to suf-
ficiently finance all the activities in the strategic plan. Other poten-
tial sources of funding include public- private partnerships, external 
funding and out of pocket payments. Due to severe budget deficit, 
the government has been failing to contribute significantly to overall 
health funding. The 2020 health budget is 10% of the total budget 
(US$21 per capita), falling short of both the Abuja declaration and 
WHO recommended threshold.43 External funding and out of pocket 
expenditure reduce universality, equity and financial protection.44
One key component of universal health coverage is equity. The 
MoHCC indicated that the Public Health Act of Zimbabwe estab-
lishes access to health services as a right to all individuals. Every 
individual chronically infected with HBV or HCV has a right to ac-
cess high- quality health services. Despite this strong legal basis for 
equity, some commercial sex workers, people who inject drugs, men 
who have sex with men and prisoners were highlighted as popula-
tions facing access barriers. Access barriers include police arrests, 
societal discrimination, stigma and insufficient community- based 
capacity. Stigma from healthcare workers was highlighted as one of 
the main barriers.
4  |  DISCUSSION
The availability of a viral hepatitis strategic plan in Zimbabwe is an 
important step towards the elimination drive because it ensures 
a coordinated and systematic way for tackling viral hepatitis. The 
elimination of viral hepatitis also depends on other health policies, 
for example the overall health, health financing policies and cor-
responding strategic plans. Currently, these policy documents lack 
the prioritization of viral hepatitis. Malaria, HIV/AIDS and non- 
communicable diseases are identified as priority areas. There is a 
dire need for dedicated funding towards viral hepatitis to address 
gaps identified in this manuscript. Another key factor to the elimina-
tion drive concerns the drafting of clear HCV and HBV treatment 
guidelines. Treatment guidelines and the essential drug list inform 
clinical practice and impact on drug access.
The strategic plan does propose a public health model to manage 
viral hepatitis in Zimbabwe. This model aims to achieve the widest 
coverage of viral hepatitis services at population level. The public 
health approach was previously implemented in Rwanda and elim-
ination of HCV is expected by 2024.45,46 Due to the high costs of 
DAAs, micro- elimination in specific areas and groups has been sug-
gested and implemented as an alternative model for the elimination 
of HCV in some settings.47,48 HCV burden is estimated to be low and 
may be prevalent in specific groups of people in Zimbabwe, making 
the micro- elimination strategy worth considering. Further work is 
required to characterize these groups in terms of size and burden 
of HCV. Micro- elimination requires modest investments and brings 
quick gains that can be used to build momentum and argue for fur-
ther investments towards national elimination.
We highlight the paucity of epidemiological data on viral hep-
atitis in Zimbabwe. Other African countries also lack robust viral 
hepatitis epidemiological data.4,5 This data are critical to inform the 
formulation of precise and effective interventions for elimination. 
The existence of the NDSS, cancer registry and health information 
systems are opportunities that require utilization. Integration of viral 
hepatitis surveillance into the existing health information systems 
and training healthcare workers on the collection of viral hepatitis 
data is urgently required. Modelling studies have been used globally 
to estimate baseline incidence and prevalence and predict impact 
of implementing treatment programmes.8,13,15 A model predicting 
HCV transmission dynamics among drugs users was developed in 
2014 for the Zimbabwean population.49 The model needs updating 
with new data on treatment regimens. Another way for estimat-
ing the prevalence of HBV and HCV is inclusion of viral hepatitis 
in HIV population- based surveys. A good example is the Zimbabwe 
Population- based HIV Impact Assessment (ZIMPHIA) in which 
population- based HIV counselling, testing and syphilis testing are 
conducted.50 A convenient and cheaper way of estimating the prev-
alence of HCV and HBV would be to use archived specimens from 
the ZIMPHIA surveys. Modelling studies and integration of viral 
hepatitis surveys to existing data collection platforms are recom-
mended for gathering of important information for action.
The coverage of HBV universal vaccination was at 90%,51 and 
this is satisfactory progress according to WHO targets.9 Efforts to 
increase uptake of HBV vaccination should be directed at the under-
performing districts to improve the figure. The programmatic chal-
lenges in implementing the HBV birth dose reported in this study are 
evident in other African nations.52 Training staff, integration of birth 
dose with maternal and new- born care, reaching infants born out of 
health institutions, task shifting, pregnancy tracking and birth notifi-
cation have been suggested as strategies, which may increase birth 
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dose coverage.53 The Zimbabwean health system has community 
health workers who can be trained, track pregnancies and admin-
ister the birth dose in the communities. Community health workers 
have been used effectively in HIV programmes,54 distribution of ma-
laria diagnostics and treatment55 and contraceptives. Other nations 
have implemented selective vaccination as opposed to universal 
vaccination and found this to be highly cost effective.56 This needs 
to be explored and considered as an alternative in Zimbabwe.
Screening and treatment are key to achieving elimination of 
viral hepatitis as demonstrated in other low- middle- income coun-
tries including Egypt and Rwanda.18 These countries embarked on 
nationwide HCV screening, universal provision of DAAs and are on 
track to achieve WHO elimination targets. In Zimbabwe, population 
screening will be costly and not feasible; hence, targeted screening is 
recommended. People who received blood and blood products be-
fore 1990, HIV positive, pregnant women, people who inject drugs, 
healthcare care workers and commercial sex workers should be con-
sidered for screening for HBV and HCV. Programmatic integration 
of viral hepatitis screening services with established health ser-
vices such HIV clinics, TB clinics and antenatal care is highly recom-
mended. The gold standard for fibrosis assessment is liver biopsy but 
may not be feasible to implement due to high costs. Non- invasive 
tests such as aspartate aminotransferase to platelet ratio index have 
been recommended in sub- Saharan Africa.4,5
HBV mono- infected patients have limited treatment options 
and the single TDF formulation is not widely available. Those with 
HBV- HIV co- infection are often inadvertently treated with TDF- 
based first- line antiretroviral regimens. This poses a risk of HBV 
flares, if TDF based regimens are changed due to treatment failure 
or kidney injury. The registered DAAs provide a sufficient arsenal 
to treat HCV. The pan- genotypic regimen sofosbuvir/daclatasvir 
is recommended to eliminate the need for genotyping.57 The gov-
ernment should engage suppliers for DAA price negotiations and 
promote use of generic drugs. Zimbabwe is covered under the vol-
untary licence agreement from manufacturers such as Gilead and 
Bristol Myers Squibb, which allows procurement of generic DAAs 
at lower prices.58 Lower prices can also be achieved through es-
tablishing collaborative agreements for pooled procurement of the 
DAAS with existing regional structures such as the Southern African 
Development Committee (SADC) and the African Union (AU). The 
procurement by the government can be refined by using tendering 
that can potentially lower the price by eliminating the middleman.
Despite its commitment to increase local funding in viral hep-
atitis at the Cairo meeting of African Union Ministers of Health,59 
the Zimbabwean government is yet to fulfil the commitment. The 
limitations in government funding are evident in the fight against 
HIV/AIDS, which is mainly funded by Global Fund and PEPFAR.60 
Since HBV/HIV or HCV/HIV co- infection is possible, advocacy for 
the inclusion of viral hepatitis in the funding cycles of these external 
agencies is required. To aid advocacy, a full investment case- based 
analysis based on the strategic plan is required. South Africa pio-
neered a national viral hepatitis investment case based on national 
guidelines.61 A multidisciplinary team looked at costing, impact 
modelling, cost- effectiveness analysis and fiscal space considerations 
for scaling up a national HCV and HBV screening and treatment pro-
gramme. The South African investment framework estimated that 
a five- year investment of US$270million would avert 13,000 HBV- 
related deaths and 7000 HCV- related deaths.61 The analysis can be 
useful as a tool to lobby for funding and establishing implementation 
parameters. We do recommend that the South African investment 
framework be adapted and adopted in Zimbabwe.
5  |  CONCLUSION
Work towards the elimination of viral hepatitis has commenced 
with the constitution of the viral hepatitis technical working group 
and drafting of the strategic plan in Zimbabwe. Strategies on track 
to contribute towards achieving the WHO elimination targets in-
clude universal three- dose hepatitis vaccination, blood donation 
screening, safe injection practices and condom distribution. The 
challenges in the path to elimination of viral hepatitis include pau-
city of epidemiological data, lack of funds, lack of the HBV vaccine 
24 h birth dose and very low to non- existent levels of screening and 
treatment.
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